Effects of Pokemon combined with survivin and cyclin B1 on glioma U251 cells by Fe 3 O 4 magnetic nanoparticles

Gliomas are the most common type of malignant brain tumors. Glioma diagnosis is not very effective, and there are few therapeutic biomarkers. The aims of this study were to detect Pokemon and its regulatory genes and explore the potential mechanism between them in glioma. The Fe 3 O 4 nanoparticles...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Materials express 2019-09, Vol.9 (6), p.616-622
Hauptverfasser: Wang, Mo, Jiang, Shengqiang, Zhang, Xu, Peng, Ruoyu, Zhu, Minghua, Zhang, Yang, Ji, Xiao, Luo, Guoxuan, Zhang, Yong
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Gliomas are the most common type of malignant brain tumors. Glioma diagnosis is not very effective, and there are few therapeutic biomarkers. The aims of this study were to detect Pokemon and its regulatory genes and explore the potential mechanism between them in glioma. The Fe 3 O 4 nanoparticles identified using TEM were used to isolate cell and tissue RNA, qRT-PCR was used to detect Pokemon, survivin, and cyclin B1 mRNA expression. Western blotting was used to detect Pokemon, survivin, and cyclin B1 protein expression. Immunofluorescence and immunohistochemistry were used to detect Pokemon expression. CCK-8 assay, EdU staining, and TUNEL staining were used to assess cell viability and apoptosis. Pokémon was over-expressed in human glioma tissue and cells. In U251 cells, Pokemon knockdown significantly decreased survivin and cyclin B1 expression, cell viability, and Pokemon expression and increased apoptosis. Pokemon overexpression had an opposite effect. In addition, over-expressed Pokemon reversed these results. Overall, we found that Pokemon promotes tumorigenesis, and the potential mechanism might be related to the Pokemon-related genes survivin and cyclin B1.
ISSN:2158-5849
DOI:10.1166/mex.2019.1527